It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...
Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...
The subcutaneous version is a co-formulation of pembrolizumab and berahyaluronidase alfa, a hyaluronidase enzyme developed by Alteogen. The enzyme temporarily hydrolyses hyaluronan in the ...
Background To determine clinical-pathologic variables in patients with a new diagnosis of hepatocellular carcinoma (HCC) and underlying hepatitis B vs. C infection. Methods Patients presenting to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback